American clinical stage biotechnology company at San Diego in California, founded in 2019, which develops RNA targeting medicines. Designs small interfering RNA and antisense oligonucleotide therapeutics with its own chemistry and delivery platforms, including RNA editing approaches, for cardiometabolic, haematological, immunological and neurological diseases, and has taken several candidates into clinical trials while partnering programmes with larger pharmaceutical companies.
Aucun commentaire disponible.
Laissez votre note & commentaire